Details of the Drug

General Information of Drug (ID: DM27ZJG)

Drug Name
AKST4290
Synonyms
Lazucirnon; ALK4290; ALK-4290; AKST4290; 1251528-23-0; Lazucirnon [USAN]; ALK429; AKST-4290; R0T9LLR4TN; BI144807; ALK-429; Lazucirnon (USAN); 2-[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]piperidin-4-yl]-5-oxopyrrolidine-2-carbonyl]amino]-N,N,6-trimethylpyridine-4-carboxamide; 2-((((2R)-1-(1-((4-Chloro-3-methylphenyl)methyl)-4-piperidinyl)-5-oxo-2-pyrrolidinyl)carbonyl)amino)-N,N,6-trimethyl-4-pyridinecarboxamide; 4-Pyridinecarboxamide, 2-((((2R)-1-(1-((4-chloro-3-methylphenyl)methyl)-4-piperidinyl)-5-oxo-2-pyrrolidinyl)carbonyl)amino)-N,N,6-trimethyl-; LAZUCIRNON [INN]; UNII-R0T9LLR4TN; SCHEMBL1668125; CHEMBL3670800; GTPL10653; BDBM123072; GLXC-26875; WHO 11481; AKOS040755379; DB15269; MS-29506; Example 11 [WO2012045803A1]; HY-136788; CS-0133685; D11741; US8742115, 11; 2-{(2R)-1-[1-(4-Chloro-3-methylbenzyl)piperidin-4-yl]-5-oxopyrrolidin-2-carboxamido}-N,N,6-trimethylpyridine-4-carboxamide
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C27H34ClN5O3
Canonical SMILES
CC1=CC(=CC(=N1)NC(=O)C2CCC(=O)N2C3CCN(CC3)CC4=CC(=C(C=C4)Cl)C)C(=O)N(C)C
InChI
InChI=1S/C27H34ClN5O3/c1-17-13-19(5-6-22(17)28)16-32-11-9-21(10-12-32)33-23(7-8-25(33)34)26(35)30-24-15-20(14-18(2)29-24)27(36)31(3)4/h5-6,13-15,21,23H,7-12,16H2,1-4H3,(H,29,30,35)/t23-/m1/s1
InChIKey
DWKNOLCXIFYNFV-HSZRJFAPSA-N
Cross-matching ID
PubChem CID
59534386
ChEBI ID
CHEMBL3670800
UNII
R0T9LLR4TN
DrugBank ID
DB15269
TTD ID
DFA0W6
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 3 (CCR3) TTD3XFU CCR3_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
C-C chemokine receptor type 3 (CCR3) DTT CCR3 2.97E-06 -0.44 -0.48
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04369430) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment. U.S.National Institutes of Health.
2 SAFETY AND THERAPEUTIC EFFECTS OF ORALLY ADMINISTERED AKST4290 IN NEWLY DIAGNOSED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2022 Jun 1;42(6):1038-1046.